Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
4(100.0%)
4Total
Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05701527Phase 1Recruiting

A Study of EBC-129 in Advanced Solid Tumours

Role: lead

NCT06513624Phase 1Recruiting

ETC-159 In Combination With Pembrolizumab In Advanced MSS/pMMR Ovarian Cancers

Role: collaborator

NCT02521844Phase 1Active Not Recruiting

A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours

Role: lead

NCT03414450Phase 1Withdrawn

Evaluation of ETC-1907206 With Dasatinib in Advanced Haematologic Malignancies

Role: lead

All 4 trials loaded